1. Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
- Author
-
Mathew Vithayathil, Antonio D'Alessio, Claudia A. M. Fulgenzi, Naoshi Nishida, Martin Schönlein, Johann von Felden, Kornelius Schulze, Henning Wege, Anwaar Saeed, Brooke Wietharn, Hannah Hildebrand, Linda Wu, Celina Ang, Thomas U. Marron, Arndt Weinmann, Peter R. Galle, Dominik Bettinger, Bertram Bengsch, Arndt Vogel, Lorenz Balcar, Bernhard Scheiner, Pei‐Chang Lee, Yi‐Hsiang Huang, Suneetha Amara, Mahvish Muzaffar, Abdul Rafeh Naqash, Antonella Cammarota, Nicola Personeni, Tiziana Pressiani, Matthias Pinter, Alessio Cortellini, Masatoshi Kudo, Lorenza Rimassa, David J. Pinato, and Rohini Sharma
- Subjects
YOUNGER ,Carcinoma, Hepatocellular ,HEPATECTOMY ,Antibodies, Monoclonal, Humanized ,IMMUNOSENESCENCE ,ADJUVANT CHEMOTHERAPY ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,anti-vascular endothelial growth factor ,RADIOFREQUENCY ABLATION ,ELDERLY-PATIENTS ,Aged ,Science & Technology ,Gastroenterology & Hepatology ,Hepatology ,cirrhosis ,Liver Neoplasms ,1103 Clinical Sciences ,CANCER ,Bevacizumab ,SORAFENIB ,checkpoint inhibitor ,anti-programmed death-ligand ,immunotherapy ,Life Sciences & Biomedicine ,PLUS BEVACIZUMAB - Abstract
Background and Aims Combination atezolizumab/bevacizumab is the gold standard for first-line treatment of unresectable hepatocellular carcinoma (HCC). Our study investigated the efficacy and safety of combination therapy in older patients with HCC. Methods 191 consecutive patients from eight centres receiving atezolizumab and bevacizumab were included. Overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and disease control rate (DCR) defined by RECIST v1.1 were measured in older (age ≥ 65 years) and younger (age
- Published
- 2022
- Full Text
- View/download PDF